|
- INDICATIONS AND USAGE DOSAGE AND ADMINISTRATION ADVERSE . . .
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use RYTELO safely and effectively See full prescribing information for
- RYTELO® (imetelstat) HCP Website | RYTELOHCP
RYTELO® (imetelstat) is indicated for treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia
- Rytelo: Package Insert Prescribing Information MOA
Rytelo package insert prescribing information for healthcare professionals Includes: indications, dosage, adverse reactions and pharmacology
- DailyMed - RYTELO- imetelstat sodium injection, powder . . .
RYTELO for injection contains imetelstat, an oligonucleotide telomerase inhibitor for intravenous use Imetelstat sodium is a white to off-white or slightly yellow, amorphous, solid powder
- Imetelstat (RYTELO) National Drug Mini-Monograph July 2025
References RYTELO (imetelstat) for intravenous injection [prescribing information online] Foster City, CA: Geron Corporation 6 2024 Available at: rytelo_pi pdf Accessed 12 9 2024
- label - Food and Drug Administration
RYTELO (imetelstat) for injection is a sterile, preservative-free, white to off-white or slightly yellow lyophilized powder for intravenous infusion after reconstitution and dilution
- RYTELO (imetelstat), FDA Approved for Treatment of Patients . . .
Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by Geron Corporation as a limited specialty pharmacy provider for RYTELOTM (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring four or more red blood cell units over eight
- HCP Resources - RYTELOHCP
Discover additional RYTELO (imetelstat) resources and information for healthcare providers to use with their patients
|
|
|